Endocrine Abstracts

Introduction: The variable tumor behavior in patients with gastro-entero-pancreatic neuroendocrine tumors (GEPNETs) is challenging. Current general biomarkers are insufficient to predict the disease course. An emerging biomarker is the NETest, a blood-based gene signature that can predict disease status based on the expression of genes involved in tumor biology. While promising, the accuracy and reproducibility of results in daily practice during years of follow up has never b...

Background: There is currently no effective blood biomarker for lung neuroendocrine neoplasia diagnosis and management. We describe the clinical utility of a 51 neuroendocrine-specific gene expression set in blood to diagnose bronchopulmonary neuroendocrine tumors (BPNETs) and define their clinical status.Methods: The discovery set included BPNETs (n=154) and controls (n=90), randomly assigned (1:1) to a test and validation set. Specifi...